Functional selectivity in adrenergic and angiotensin signaling systems

Molecular Pharmacology

Volumn 78, Issue 6, 2010, Pages 983-992

  Patel, Chetan B ^a   Noor, Nabila ^b   Rockman, Howard A ^a  

^a Department of Medicine ^*  (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1A RECEPTOR; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN; BETAXOLOL; BISOPROLOL; CAD PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CANDESARTAN; CARVEDILOL; CHIMERIC PROTEIN; CYCLIC AMP; EPIDERMAL GROWTH FACTOR RECEPTOR; ESMOLOL; G PROTEIN COUPLED RECEPTOR KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN; LABETALOL; METOPROLOL; MITOGEN ACTIVATED PROTEIN KINASE; NADOLOL; OXPRENOLOL; PENBUTOLOL; PINDOLOL; PRACTOLOL; PROPAFENONE; PROPANOL; SOTALOL; TIMOLOL; UNINDEXED DRUG;

ADRENERGIC ACTIVITY; ADRENERGIC SYSTEM; ANGIOTENSIN BLOOD LEVEL; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE CONTROL; GENE MUTATION; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN POLYMORPHISM; REACTOR CASCADE; RECEPTOR DOWN REGULATION; SHORT SURVEY; SIGNAL TRANSDUCTION;

ADRENERGIC AGENTS; ANGIOTENSINS; ANIMALS; ARRESTINS; GTP-BINDING PROTEINS; HUMANS; RECEPTORS, ADRENERGIC; RECEPTORS, ANGIOTENSIN; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 78649918839     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.067066     Document Type: Short Survey

References (70)

1. Ahn S, Kim J, Hara MR, Ren XR, and Lefkowitz RJ (2009) {beta}-Arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphorylation. J Biol Chem 284:8855-8865.
2. Ahn S, Shenoy SK, Wei H, and Lefkowitz RJ (2004) Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem 279:35518-35525. (Pubitemid 39100552)
3. Akhter SA, D'Souza KM, Petrashevskaya NN, Mialet-Perez J, and Liggett SB (2006) Myocardial beta1-adrenergic receptor polymorphisms affect functional recovery after ischemic injury. Am J Physiol Heart Circ Physiol 290:H1427-H1432.
4. Allan LA, Morrice N, Brady S, Magee G, Pathak S, and Clarke PR (2003) Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 5:647-654.
5. Amant C, Hamon M, Bauters C, Richard F, Helbecque N, McFadden EP, Escudero X, Lablanche JM, Amouyel P, and Bertrand ME (1997) The angiotensin II type 1 receptor gene polymorphism is associated with coronary artery vasoconstriction. J Am Coll Cardiol 29:486-490.
6. Aplin M, Christensen GL, Schneider M, Heydorn A, Gammeltoft S, Kjølbye AL, Sheikh SP, and Hansen JL (2007) The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and langendorff-perfused hearts. Basic Clin Pharmacol Toxicol 100:289-295. (Pubitemid 46633483)
7. Baker JG, Hall IP, and Hill SJ (2003) Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 64:1357-1369.
8. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869.
9. Charest PG, Terrillon S, and Bouvier M (2005) Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET. EMBO Rep 6:334-340.
10. Christensen GL, Kelstrup CD, Lyngsø C, Sarwar U, Bøgebo R, Sheikh SP, Gammeltoft S, Olsen JV, and Hansen JL (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9:1540-1553.
11. Daaka Y, Luttrell LM, and Lefkowitz RJ (1997) Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 390:88-91. (Pubitemid 27494762)
12. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995-1003. (Pubitemid 34286536)
13. de Denus S, Zakrzewski-Jakubiak M, Dubé MP, Bélanger F, Lepage S, Leblanc MH, Gossard D, Ducharme A, Racine N, Whittom L, et al. (2008) Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan. Ann Pharmacother 42:925-932.
14. DeWire SM, Ahn S, Lefkowitz RJ, and Shenoy SK (2007) Beta-arrestins and cell signaling. Annu Rev Physiol 69:483-510.
15. Drake MT, Violin JD, Whalen EJ, Wisler JW, Shenoy SK, and Lefkowitz RJ (2008) beta-arrestin-biased agonism at the beta2-adrenergic receptor. J Biol Chem 283:5669-5676.
16. Gáborik Z, Jagadeesh G, Zhang M, Spät A, Catt KJ, and Hunyady L (2003) The role of a conserved region of the second intracellular loop in AT1 angiotensin receptor activation and signaling. Endocrinology 144:2220-2228.
17. Galandrin S and Bouvier M (2006) Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70:1575-1584.
18. Galandrin S, Oligny-Longpré G, and Bouvier M (2007) The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci 28:423-430.
19. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR, and Kobilka BK (2001) Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem 276:24433-24436.
20. Granier S, Kim S, Shafer AM, Ratnala VR, Fung JJ, Zare RN, and Kobilka B (2007) Structure and conformational changes in the C-terminal domain of the beta2- adrenoceptor: insights from fluorescence resonance energy transfer studies. J Biol Chem 282:13895-13905.
21. Graves LM, Guy HI, Kozlowski P, Huang M, Lazarowski E, Pope RM, Collins MA, Dahlstrand EN, Earp HS 3rd, and Evans DR (2000) Regulation of carbamoyl phosphate synthetase by MAP kinase. Nature 403:328-332.
22. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vítovec J, Aldershvile J, et al. (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283:1295-1302.
23. Jarpe MB, Widmann C, Knall C, Schlesinger TK, Gibson S, Yujiri T, Fanger GR, Gelfand EW, and Johnson GL (1998) Anti-apoptotic versus pro-apoptotic signal transduction: checkpoints and stop signs along the road to death. Oncogene 17:1475-1482.
24. Kenakin T (2001) Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15:598-611.
25. Kenakin T (2003) Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 24:346-354.
26. Kenakin T (2004) Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25:186-192.
27. Kenakin T (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4:919-927.
28. Kenakin T and Miller LJ (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62:265-304.
29. Kenakin TP (2009) '7TM receptor allostery: putting numbers to shapeshifting proteins. Trends Pharmacol Sci 30:460-469.
30. Kim IM, Tilley DG, Chen J, Salazar NC, Whalen EJ, Violin JD, and Rockman HA (2008) Beta-blockers alprenolol and carvedilol stimulate beta-arrestin- mediated EGFR transactivation. Proc Natl Acad Sci USA 105:14555-14560.
31. Kim J, Ahn S, Rajagopal K, and Lefkowitz RJ (2009) Independent beta-arrestin2 and Gq/protein kinase Czeta pathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor. J Biol Chem 284:11953-11962.
32. Kim J, Ahn S, Ren XR, Whalen EJ, Reiter E, Wei H, and Lefkowitz RJ (2005) Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. Proc Natl Acad Sci USA 102:1442-1447. (Pubitemid 40209189)
33. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, and Spertus JA (2005) Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA 294:1526-1533. (Pubitemid 41362690)
34. Lefkowitz RJ (1998) G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem 273:18677-18680.
35. Lefkowitz RJ and Shenoy SK (2005) Transduction of receptor signals by betaarrestins. Science 308:512-517.
36. Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, Diwan A, Martini JS, Sparks L, Parekh RR, et al. (2008) A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 14:510-517.
37. Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, and Auberger P (2003) Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 22:6785-6793.
38. Luttrell LM, Hawes BE, van Biesen T, Luttrell DK, Lansing TJ, and Lefkowitz RJ (1996) Role of c-Src tyrosine kinase in G protein-coupled receptor- and Gbetagamma subunit-mediated activation of mitogen-activated protein kinases. J Biol Chem 271:19443-19450.
39. Mangmool S, Shukla AK, and Rockman HA (2010) beta-Arrestin-dependent activation of Ca(2+)/calmodulin kinase II after beta(1)-adrenergic receptor stimulation. J Cell Biol 189:573-587.
40. Martin NP, Whalen EJ, Zamah MA, Pierce KL, and Lefkowitz RJ (2004) PKA-mediated phosphorylation of the beta1-adrenergic receptor promotes Gs/Gi switching. Cell Signal 16:1397-1403.
41. Maudsley S, Pierce KL, Zamah AM, Miller WE, Ahn S, Daaka Y, Lefkowitz RJ, and Luttrell LM (2000) The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem 275:9572-9580.
42. McKay MM and Morrison DK (2007) Integrating signals from RTKs to ERK/MAPK. Oncogene 26:3113-3121.
43. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, Dorn GW, and Liggett SB (2003) Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9:1300-1305.
44. Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, Chen J, Le Corvoisier P, Violin JD, Wei H, Lefkowitz RJ, et al. (2007) Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 117:2445-2458.
45. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, et al. (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106:2194-2199.
46. Pierce KL, Maudsley S, Daaka Y, Luttrell LM, and Lefkowitz RJ (2000) Role of endocytosis in the activation of the extracellular signal-regulated kinase cascade by sequestering and nonsequestering G protein-coupled receptors. Proc Natl Acad Sci USA 97:1489-1494.
47. Rajagopal K, Whalen EJ, Violin JD, Stiber JA, Rosenberg PB, Premont RT, Coffman TM, Rockman HA, and Lefkowitz RJ (2006) Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci USA 103:16284-16289.
48. Rajagopal S, Rajagopal K, and Lefkowitz RJ (2010) Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9:373-386.
49. Rakesh K, Yoo B, Kim IM, Salazar N, Kim KS, and Rockman HA (2010) beta- Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci Signal 3:ra46.
50. Rochais F, Vilardaga JP, Nikolaev VO, Bünemann M, Lohse MJ, and Engelhardt S (2007) Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest 117:229-235.
51. Rockman HA, Koch WJ, and Lefkowitz RJ (2002) Seven-transmembrane-spanning receptors and heart function. Nature 415:206-212.
52. Rozengurt E (2007) Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol 213:589-602.
53. Sehnert AJ, Daniels SE, Elashoff M, Wingrove JA, Burrow CR, Horne B, Muhlestein JB, Donahue M, Liggett SB, Anderson JL, et al. (2008) Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol 52:644-651.
54. Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, Reiter E, Premont RT, Lichtarge O, and Lefkowitz RJ (2006) beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem 281:1261-1273.
55. Shin J, Lobmeyer MT, Gong Y, Zineh I, Langaee TY, Yarandi H, Schofield RS, Aranda JM Jr, Hill JA, Pauly DF, et al. (2007) Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol 99:250-255.
56. Shukla AK, Violin JD, Whalen EJ, Gesty-Palmer D, Shenoy SK, and Lefkowitz RJ (2008) Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors. Proc Natl Acad Sci USA 105:9988-9993.
57. Spiering W, Kroon AA, Fuss-Lejeune MM, Daemen MJ, and de Leeuw PW (2000) Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(1166)C polymorphism in essential hypertensives on a high sodium diet. Hypertension 36:411-416.
58. Stefanovsky V, Langlois F, Gagnon-Kugler T, Rothblum LI, and Moss T (2006) Growth factor signaling regulates elongation of RNA polymerase I transcription in mammals via UBF phosphorylation and r-chromatin remodeling. Mol Cell 21:629-639. (Pubitemid 43290730)
59. Strachan RT, Sciaky N, Cronan MR, Kroeze WK, and Roth BL (2010) Genetic deletion of p90 ribosomal S6 kinase 2 alters patterns of 5-hydroxytryptamine 2A serotonin receptor functional selectivity. Mol Pharmacol 77:327-338.
60. Tohgo A, Choy EW, Gesty-Palmer D, Pierce KL, Laporte S, Oakley RH, Caron MG, Lefkowitz RJ, and Luttrell LM (2003) The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. J Biol Chem 278:6258-6267.
61. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13.
62. Violin JD, Ren XR, and Lefkowitz RJ (2006) G-protein-coupled receptor kinase specificity for beta-arrestin recruitment to the beta2-adrenergic receptor revealed by fluorescence resonance energy transfer. J Biol Chem 281:20577-20588.
63. Waskiewicz AJ, Flynn A, Proud CG, and Cooper JA (1997) Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 16:1909-1920.
64. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, and Lefkowitz RJ (2003) Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100:10782-10787.
65. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, Shenoy SK, and Lefkowitz RJ (2007) A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci USA 104:16657-16662.
66. Xiao K, McClatchy DB, Shukla AK, Zhao Y, Chen M, Shenoy SK, Yates JR 3rd, and Lefkowitz RJ (2007) Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci USA 104:12011-12016.
67. Xiao K, Sun J, Kim J, Rajagopal S, Zhai B, Villén J, Haas W, Kovacs JJ, Shukla AK, Hara MR, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci USA 107:15299-15304.
68. Zhai P, Yamamoto M, Galeotti J, Liu J, Masurekar M, Thaisz J, Irie K, Holle E, Yu X, Kupershmidt S, et al. (2005) Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 115:3045-3056.
69. Zhu WZ, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK, and Xiao RP (2001) Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA 98:1607-1612.
70. Zou Y, Komuro I, Yamazaki T, Kudoh S, Aikawa R, Zhu W, Shiojima I, Hiroi Y, Tobe K, Kadowaki T, et al. (1998) Cell type-specific angiotensin II-evoked signal transduction pathways: critical roles of Gbetagamma subunit, Src family, and Ras in cardiac fibroblasts. Circ Res 82:337-345.